• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Gone with wind: a novel biodegradable occluder for percutaneous closure of patent foramen ovale
A 42-year-old man with a history of cryptogenic stroke and sequela free after medical therapy was found to have a patent foramen ovale (PFO) by transoesophageal echocardiography (TEE,Panel A, arrowhead indicates the PFO; Ao, aorta; LA, left atrium; RA, right atrium). Given a RoPE score of 7, he was referred for percutaneous PFO closure. A 24  mm × 24 mm fully biodegradable occluder (Pancy® occluder, ChiCTR1900024036,Panel E, arrowhead indicates marker) was delivered and deployed via a 10-Fr sheath (Mallow® delivery system) under florescent angiography and TEE (Panel B, arrowhead indicates the marker on occluder while ...
Source: European Heart Journal - October 2, 2020 Category: Cardiology Source Type: research

Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials
ConclusionIn selected patients with cryptogenic stroke, PFO closure is superior to medical therapy for the prevention of further stroke: this is particularly true for patients with moderate-to-large shunts. Guidelines should be updated to reflect this.
Source: European Heart Journal - March 24, 2018 Category: Cardiology Source Type: research

Foreign body granuloma as an unexpected long-term finding after percutaneous closure of a patent foramen ovale
A 67-year-old man was referred to our hospital for catheter ablation of atrial fibrillation. Eight years earlier, prior to diagnosis of atrial fibrillation, the patient suffered an ischaemic stroke. A patent foramen ovale (PFO) was diagnosed and the patient underwent percutaneous PFO closure by implantation of a Premere device (20  mm, St. Jude Medical). One month ago, the patient had another middle-cerebral artery infarction, which was considered cardioembolic due to insufficient anticoagulation. However, transthoracic echocardiography (TTE) obtained on current admission demonstrated a suspicious mass in the left atrium...
Source: European Heart Journal - March 24, 2017 Category: Cardiology Source Type: research

Percutaneous closure of patent foramen ovale: an underutilized prevention?
Stroke is a devastating event for patients and their families. Paradoxical embolism through a patent foramen ovale (PFO) is a recognized cause of stroke. Percutaneous PFO closure is a simple and safe procedure. The debate on PFO closure is far from settled. This is, in part, due to the fact that the three published randomized controlled trials (RCTs) on PFO closure vs. medical therapy were negative regarding their primary endpoint; however, as-treated and per-protocol analyses as well as several meta-analyses report a benefit of PFO closure. In our opinion, PFO closure is underutilized and the results of the three RCTs are...
Source: European Heart Journal - July 10, 2016 Category: Cardiology Authors: Nietlispach, F., Meier, B. Tags: Clinical update Source Type: research

Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis
Conclusion We did not find a statistically significant difference comparing OAC with APT; our results justify randomized trials comparing different antithrombotic approaches in these patients.
Source: European Heart Journal - September 14, 2015 Category: Cardiology Authors: Kent, D. M., Dahabreh, I. J., Ruthazer, R., Furlan, A. J., Weimar, C., Serena, J., Meier, B., Mattle, H. P., Di Angelantonio, E., Paciaroni, M., Schuchlenz, H., Homma, S., Lutz, J. S., Thaler, D. E. Tags: Thrombosis and antithrombotic therapy Source Type: research

Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis
Conclusions The effectiveness of PFO closure depends on the device used. PFO closure with AMP appears superior to medical therapy in preventing strokes in patients with cryptogenic embolism.
Source: European Heart Journal - January 12, 2015 Category: Cardiology Authors: Stortecky, S., da Costa, B. R., Mattle, H. P., Carroll, J., Hornung, M., Sievert, H., Trelle, S., Windecker, S., Meier, B., Juni, P. Tags: Vascular medicine Source Type: research

Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials
Conclusion These results suggest that in patients with cryptogenic stroke, TC PFO closure may be beneficial in reducing the risk of recurrent vascular events when compared to medical treatment. The benefit of TC PFO closure may be greater in patients with a substantial shunt.
Source: European Heart Journal - November 14, 2013 Category: Cardiology Authors: Rengifo-Moreno, P., Palacios, I. F., Junpaparp, P., Witzke, C. F., Morris, D. L., Romero-Corral, A. Tags: International cardiology Source Type: research

Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale
Conclusion Although procedural complications and long-term neurological event rates are low regardless of the device used, the recurrent neurological event rate was significantly lower after Amplatzer than after CardioSEAL-STARflex or Helex implantation. This has important implications regarding the interpretation of trials comparing PFO closure with medical management.
Source: European Heart Journal - November 14, 2013 Category: Cardiology Authors: Hornung, M., Bertog, S. C., Franke, J., Id, D., Taaffe, M., Wunderlich, N., Vaskelyte, L., Hofmann, I., Sievert, H. Tags: Interventional cardiology Source Type: research